Drug Profile
Vinflunine - Pierre Fabre
Alternative Names: F-12158; Javlor; L-0070; Vinflunine ditartrateLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Pierre Fabre
- Class Antineoplastics; Vinca alkaloids
- Mechanism of Action Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Bladder cancer
- Preregistration Breast cancer
- Phase III Head and neck cancer; Urogenital cancer
- No development reported Malignant-mesothelioma; Non-small cell lung cancer; Solid tumours
- Discontinued Gastric cancer; Ovarian cancer
Most Recent Events
- 01 Mar 2022 Vinflunine is still not available for Bladder cancer (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in Chile (IV) (NDR batch 21)
- 28 Mar 2019 Registered for Bladder cancer (Monotherapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Chile (IV)
- 23 Nov 2018 Pierre Fabre Medicament completes a phase III trial in Head and neck cancer (Combination therapy, Locally recurrent, Metastatic disease, Second-line therapy or greater) in Austria, Belgium, Estonia, Germany, Poland, Slovakia, Spain, France and Italy (IV) (NCT02347332) (EudraCT2011-005081-38)